Charles River Laboratories Announces First-Quarter 2019 Results
– First-Quarter Revenue of $604.6 Million – – First-Quarter GAAP Earnings per Share of $1.11 and Non-GAAP Earnings per Share…
Pharmaceuticals, Biotechnology and Life Sciences
– First-Quarter Revenue of $604.6 Million – – First-Quarter GAAP Earnings per Share of $1.11 and Non-GAAP Earnings per Share…
SYRACUSE, N.Y.–(BUSINESS WIRE)–Repair Biotechnologies, Inc. announced today $2.15 million in seed venture funding, to accelerate the preclinical development of its…
Open-label, long-term extension data show durability of zilucoplan treatment effect, with sustained improvements observed in primary and secondary endpoints at…
– Process Could Significantly Reduce Cannabinoid Production Time – TORONTO–(BUSINESS WIRE)–lt;a href="https://twitter.com/hashtag/FSDDF?src=hash" target="_blank"gt;#FSDDFlt;/agt;–FSD Pharma Inc. (CSE: HUGE) (OTC: FSDDF) (FRA:…
NEW YORK–(BUSINESS WIRE)–Rocket Pharmaceuticals, Inc. (NASDAQ: RCKT) (“Rocket”), a leading U.S.-based multi-platform clinical-stage gene therapy company, today announces that Gaurav Shah,…
— Q1 2019 net income of $0.64 per basic and $0.62 per diluted share and adjusted non-GAAP net income of…
First Randomized Controlled Polysomnography Trial of Insomnia Medication in Alzheimer’s Disease Dementia Population Data to be Filed with FDA for…
— Statistically significant lower incidence of brain damage compared to control group, demonstrating neuroprotective properties of RYANODEX in treating nerve…
Algiax Pharmaceuticals Appoints Dr. Ingo Lehrke and Dr. Guido Koopmans as CEO and CSO. A Proof-of-Concept Study for Neuropathic Pain…
Company to Develop Gene Editing Therapies to Permanently Reduce Risk of Coronary Artery Disease in Adults Announces Key Licensing Agreements…